GLP-1 Drugs Hit 11.4% of Pharmacy Claims. Coverage Is Getting Harder, Not Easier.

Your company's health plan probably doesn't cover Wegovy or Zepbound for weight loss. If it does, the rules just got tighter, not looser.

GLP-1 drugs went from 6.9% of annual pharmacy claims in 2023 to 11.4% in 2026. That's the finding of the International Foundation of Employee Benefit Plans' 2026 Pulse Survey, first reported by CNBC in July. Some employers are dropping the benefit outright.

More are handing the bill to employees instead. They point workers toward a direct-to-consumer platform, or toward their own FSA, HSA, or HRA balance.

Neither move is expansion. Both let a company say it's addressing GLP-1 demand without absorbing the cost of it.

The Squeeze Nobody Budgeted For

A single month of Wegovy or Zepbound runs over $1,000 before rebates, per Mercer's 2026 GLP-1 Q&A for plan sponsors. Generic competition is more than five years out. That price isn't dropping on its own timeline.

The claims data backs up the anxiety. GLP-1 spend now consumes more than 15% of total annual claims for over a quarter of large employers, per IFEBP.

That's one drug category eating a sixth of the pharmacy budget. Benefits teams are used to spreading risk across hundreds of drugs, not one.

What Employers Are Actually Doing Instead

Twenty-seven percent of employers are steering employees toward direct-to-consumer platforms, per IFEBP. Those are the cash-price channels Eli Lilly and Novo Nordisk built to sell Zepbound and Wegovy outside insurance. Another 21% point employees toward their own FSA, HSA, or HRA balance instead.

Neither move reduces access on paper. Both shift the cost off the pharmacy line. It lands on the employee's paycheck, or on an account they were already funding for something else.

For employers who keep coverage, the rules are getting stricter. More than a quarter of large employers are tightening eligibility criteria heading into 2026 and 2027, per Mercer.

About half now require a BMI threshold plus a second qualifying condition, not obesity alone. Roughly 38% require enrollment in a lifestyle or weight-management program just to keep the prescription approved, per HR Executive.

The Legal Wrinkle Benefits Teams Keep Underestimating

Cutting a drug category from the formulary sounds like a simple cost lever. It isn't, once obesity's comorbidities enter the picture.

Morgan Lewis laid out the risk in a January 2026 client note. Most federal appeals courts don't treat ordinary obesity as an ADA disability on its own.

But diabetes, cardiovascular disease, and sleep apnea often ride alongside a GLP-1 prescription. Those conditions are independently protected in many cases.

An exclusion written broadly enough to catch those comorbidities too can create exposure a plan sponsor never intended.

Fisher Phillips reaches a similar conclusion in its employer FAQ on GLP-1s. No federal appeals court has ruled that a weight-loss exclusion itself is disability discrimination. But litigation testing that exact question is already underway.

Here's the wrinkle most plan documents miss. The FDA approved Zepbound in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity, per Eli Lilly's announcement.

That's a separate indication from weight loss. A plan that excludes GLP-1s "for weight loss" may still owe coverage for the identical drug prescribed for sleep apnea.

Read your exclusion language literally. It probably doesn't say what you assume it says.

Who's Dropping Coverage, Who's Doubling Down

The split is real, and it isn't subtle.

Blue Cross Blue Shield of Massachusetts stopped covering GLP-1s for weight loss under standard plans starting January 1, 2026. Employers with fewer than 100 workers lose the benefit automatically at renewal. Its CFO cited GLP-1 spend that hit $300 million in a single year, double the year before.

Harvard Pilgrim Health Care and Blue Cross Blue Shield of Michigan made the same call for 2026.

HCA Healthcare, one of the country's largest hospital operators, told employees it would stop covering Zepbound and Wegovy. Internal usage had jumped 90% in a year. Its fallback: enroll in the manufacturers' own cash-pay discount programs.

Then there's Bank of America, spending an estimated $250 million a year on GLP-1 coverage inside a broader wellness budget. CEO Brian Moynihan's reasoning wasn't charitable.

It was actuarial. Lower near-term cardiac risk across a large population is "the payback," he says.

Two large employers, running the same math, landing on opposite conclusions. That tells you the "right" answer hasn't been found. It's being negotiated, plan by plan, renewal by renewal.

See What Your Coverage Tier Actually Costs

The tool below models common coverage scenarios against a full year of GLP-1 therapy. It won't match your actual invoice. Rebates, plan-specific copay structures, and manufacturer coupon terms all move the real number.

What it will show is the gap between "my plan covers it" and "my plan doesn't." That gap is usually the whole story.

The Angle National Coverage Keeps Missing

GLP-1 use skews toward people who can pay for it without a fight. That's exactly the population reading this.

Residents of wealthier states like Massachusetts, Connecticut, and California face an out-of-pocket burden below 8% of per capita income for a year of injectable therapy. Lower-income states like Mississippi and West Virginia see burdens above 12%, per The Health Management Academy's 2026 affordability analysis.

That changes the calculus for a Scarsdale or Rye executive in a way most national coverage skips past. If your household can absorb $1,000 a month in cash while your plan sorts out its 2027 formulary, the real question isn't access.

It's whether pursuing a coverage appeal is worth the time. A direct-to-consumer subscription and the family's HSA might just solve the problem faster.

It also means the executive tier carries more ADA-adjacent leverage than most benefits teams account for. A senior leader managing diabetes or sleep apnea alongside a GLP-1 prescription has a stronger comorbidity argument in a coverage dispute than most exclusion language anticipates.

Few benefits teams think about that leverage from the employee side. Fewer employees think to ask.

What to Actually Ask Before Renewal

Stop asking whether GLP-1s are covered. Ask which indication triggers coverage. Weight loss, diabetes, and sleep apnea are increasingly three separate questions under the same plan, with three separate answers.

Ask what the lifestyle-program requirement actually involves before assuming it's a formality. Roughly 38% of employers now tie continued coverage to enrollment in one, per HR Executive.

And if your plan doesn't cover it, that isn't the end of the conversation. Direct-to-consumer cash pricing and FSA or HSA reimbursement both remain live options, regardless of what the formulary says. For a lot of households in this readership, one of those two paths beats a benefits appeal on speed alone.

Last updated August 2026. This article is not medical, legal, or benefits-plan advice. Coverage terms, eligibility criteria, and reimbursement rules vary by employer, insurer, and plan year.

Consult your plan administrator, a licensed benefits broker, or qualified counsel before making a decision.